<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03109730</url>
  </required_header>
  <id_info>
    <org_study_id>ABI-H0731-101B</org_study_id>
    <nct_id>NCT03109730</nct_id>
  </id_info>
  <brief_title>Phase 1b/2a Study of ABI-H0731 in Patients With Chronic Hepatitis B</brief_title>
  <official_title>A Phase 1b/2a, Dose-Ranging Study of the Safety, Tolerability, Pharmacokinetics, and Initial Efficacy of ABI-H0731 in Patients With Chronic Hepatitis B</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assembly Biosciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assembly Biosciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this protocol is to obtain pharmacodynamic and pharmacokinetic data on
      ABI-H0731 and to provide the opportunity for preliminary evaluation of combination therapy of
      ABI-H0731 with currently approved antiviral treatment for chronic hepatitis B.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Phase 1b/2a assessments of the dose-related safety, PK, and initial antiviral efficacy of
      ABI-H0731 in hepatitis B patients will be conducted at approximately 17 different sites to
      meet enrollment goals of 108 chronic hepatitis B patients.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 15, 2017</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Actual">March 31, 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with chronic HBV infection with treatment-related adverse events and laboratory abnormalities as assessed by CTCAE v4.0.</measure>
    <time_frame>Up to 57 days</time_frame>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">84</enrollment>
  <condition>Chronic Hepatitis B</condition>
  <arm_group>
    <arm_group_label>Cohort B1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABI-H0731 or Placebo in varying doses by mouth for 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABI-H0731 or Placebo in varying doses by mouth for 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABI-H0731 or Placebo in varying doses by mouth for 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABI-H0731 or Placebo in varying doses by mouth for 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABI-H0731 or Placebo in combination with entecavir or tenofovir for 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABI-H0731 or Placebo, in combination with a commerically-approved nucleos(t)ide plus PegIFN in treatment-experienced patients, for 28 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABI-H0731</intervention_name>
    <description>A novel HBV core protein allosteric modifier (CpAM) which is being developed as a potential therapeutic advance for CHB patients</description>
    <arm_group_label>Cohort B1</arm_group_label>
    <arm_group_label>Cohort B2</arm_group_label>
    <arm_group_label>Cohort B3</arm_group_label>
    <arm_group_label>Cohort B4</arm_group_label>
    <arm_group_label>Cohort B5</arm_group_label>
    <arm_group_label>Cohort B6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo for ABI-H0731</intervention_name>
    <description>Sugar pill manufactured to mimic the ABI-H0731 tablet</description>
    <arm_group_label>Cohort B1</arm_group_label>
    <arm_group_label>Cohort B2</arm_group_label>
    <arm_group_label>Cohort B3</arm_group_label>
    <arm_group_label>Cohort B4</arm_group_label>
    <arm_group_label>Cohort B5</arm_group_label>
    <arm_group_label>Cohort B6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Entecavir</intervention_name>
    <description>An antiviral medication used in the treatment of hepatitis B virus infection</description>
    <arm_group_label>Cohort B5</arm_group_label>
    <other_name>ETV</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenofovir Disoproxil Fumarate</intervention_name>
    <description>An antiviral medication used in the treatment of hepatitis B virus infection</description>
    <arm_group_label>Cohort B5</arm_group_label>
    <other_name>TDF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegasys</intervention_name>
    <description>Used to treat adults with chronic hepatitis B virus who show signs of liver damage</description>
    <arm_group_label>Cohort B6</arm_group_label>
    <other_name>peginterferon alfa-2a</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female, 18 to 65 years of age

          -  Chronic HBV infection

          -  Body Mass Index (BMI) 18-38 kg/m2 and a minimum body weight of 45 kg

        Exclusion Criteria:

          -  Seropositive for HIV, HCV, or HDV antibody at Screen

          -  Previous treatment with any investigational HBV antiviral treatments within the last 6
             months

          -  Other known cause of liver disease, including NASH

          -  Other medical condition that requires persistent medical management or chronic or
             recurrent pharmacologic or surgical intervention
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Monash University</name>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincent's Hospital</name>
      <address>
        <city>Fitzroy</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Alfred Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Linear Clinical Research</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Hong Kong</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hallym University</name>
      <address>
        <city>Chuncheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHA Bundang Medical Center</name>
      <address>
        <city>Gyeonggi-do</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Severance Hospital, Yonsei University</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Keelung Chang Gung Memorial Hospital</name>
      <address>
        <city>Keelung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>King's College Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Free Hospital NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal London Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Hong Kong</country>
    <country>Korea, Republic of</country>
    <country>Taiwan</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>New Zealand</country>
  </removed_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 6, 2017</study_first_submitted>
  <study_first_submitted_qc>April 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 12, 2017</study_first_posted>
  <last_update_submitted>April 25, 2018</last_update_submitted>
  <last_update_submitted_qc>April 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Peginterferon alfa-2a</mesh_term>
    <mesh_term>Entecavir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

